#ID(s) interactor A	ID(s) interactor B	Alt. ID(s) interactor A	Alt. ID(s) interactor B	Alias(es) interactor A	Alias(es) interactor B	Interaction detection method(s)	Publication 1st author(s)	Publication Identifier(s)	Taxid interactor A	Taxid interactor B	Interaction type(s)	Source database(s)	Interaction identifier(s)	Confidence value(s)	Expansion method(s)	Biological role(s) interactor A	Biological role(s) interactor B	Experimental role(s) interactor A	Experimental role(s) interactor B	Type(s) interactor A	Type(s) interactor B	Xref(s) interactor A	Xref(s) interactor B	Interaction Xref(s)	Annotation(s) interactor A	Annotation(s) interactor B	Interaction annotation(s)	Host organism(s)	Interaction parameter(s)	Creation date	Update date	Checksum(s) interactor A	Checksum(s) interactor B	Interaction Checksum(s)	Negative	Feature(s) interactor A	Feature(s) interactor B	Stoichiometry(s) interactor A	Stoichiometry(s) interactor B	Identification method participant A	Identification method participant B
uniprotkb:Q03591-PRO_0000005896	uniprotkb:P01024	intact:EBI-22118464	intact:EBI-905851|uniprotkb:A7E236|ensembl:ENSP00000245907	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:co3_human(display_long)|uniprotkb:C3(gene name)|psi-mi:C3(display_short)|uniprotkb:CPAMD1(gene name synonym)|uniprotkb:C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1(gene name synonym)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184629|imex:IM-27467-1	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:0326"(protein)	intact:EBI-3935840(chain-parent)	refseq:NP_000055.2|dip:DIP-35180N|ensembl:ENSG00000125730(gene)|ensembl:ENST00000245907(transcript)|go:"GO:0001798"(positive regulation of type IIa hypersensitivity)|go:"GO:0001934"(positive regulation of protein phosphorylation)|go:"GO:0001970"(positive regulation of activation of membrane attack complex)|go:"GO:0004866"(endopeptidase inhibitor activity)|go:"GO:0005102"(signaling receptor binding)|go:"GO:0005576"(extracellular region)|go:"GO:0005615"(extracellular space)|go:"GO:0005788"(endoplasmic reticulum lumen)|go:"GO:0005886"(plasma membrane)|go:"GO:0006631"(fatty acid metabolic process)|go:"GO:0006954"(inflammatory response)|go:"GO:0006955"(immune response)|go:"GO:0006956"(complement activation)|go:"GO:0006957"(complement activation, alternative pathway)|go:"GO:0006958"(complement activation, classical pathway)|go:"GO:0007165"(signal transduction)|go:"GO:0007186"(G protein-coupled receptor signaling pathway)|go:"GO:0009617"(response to bacterium)|go:"GO:0009986"(cell surface)|go:"GO:0010575"(positive regulation of vascular endothelial growth factor production)|go:"GO:0010828"(positive regulation of glucose transmembrane transport)|go:"GO:0010866"(regulation of triglyceride biosynthetic process)|go:"GO:0010884"(positive regulation of lipid storage)|go:"GO:0016322"(neuron remodeling)|go:"GO:0031715"(C5L2 anaphylatoxin chemotactic receptor binding)|go:"GO:0032991"(protein-containing complex)|go:"GO:0034774"(secretory granule lumen)|go:"GO:0035578"(azurophil granule lumen)|go:"GO:0035846"(oviduct epithelium development)|go:"GO:0045745"(positive regulation of G protein-coupled receptor signaling pathway)|go:"GO:0045766"(positive regulation of angiogenesis)|go:"GO:0048260"(positive regulation of receptor-mediated endocytosis)|go:"GO:0060100"(positive regulation of phagocytosis, engulfment)|go:"GO:0070062"(extracellular exosome)|go:"GO:0072562"(blood microparticle)|go:"GO:0097242"(amyloid-beta clearance)|go:"GO:0097278"(complement-dependent cytotoxicity)|go:"GO:0150062"(complement-mediated synapse pruning)|go:"GO:0150064"(vertebrate eye-specific patterning)|go:"GO:1905114"(cell surface receptor signaling pathway involved in cell-cell signaling)|go:"GO:2000427"(positive regulation of apoptotic cell clearance)|interpro:IPR000020(Anaphylatoxin/fibulin)|interpro:IPR001134(Netrin, C-terminal)|interpro:IPR001599(Alpha-2-macroglobulin)|interpro:IPR001840(Complement C3a/C4a/C5a anaphylatoxin)|interpro:IPR002890(Alpha-2-macroglobulin, N-terminal)|interpro:IPR008930(Terpenoid cylases/protein prenyltransferase alpha-alpha toroid)|interpro:IPR008993(TIMP-like, OB-fold)|interpro:IPR009048(Alpha-macroglobulin, receptor-binding)|interpro:IPR011625(Alpha-2-macroglobulin, N-terminal 2)|interpro:IPR011626(A-macroglobulin complement component)|interpro:IPR013783(Immunoglobulin-like fold)|interpro:IPR018081|interpro:IPR018933|interpro:IPR019742|interpro:IPR035711|interpro:IPR035815|interpro:IPR036595|interpro:IPR040839|interpro:IPR041425|interpro:IPR041555|mint:P01024|rcsb pdb:1C3D|rcsb pdb:1GHQ|rcsb pdb:1W2S|rcsb pdb:2A73|rcsb pdb:2A74|rcsb pdb:2GOX|rcsb pdb:2I07|rcsb pdb:2ICE|rcsb pdb:2ICF|rcsb pdb:2NOJ|rcsb pdb:2QKI|rcsb pdb:2WII|rcsb pdb:2WIN|rcsb pdb:2WY7|rcsb pdb:2WY8|rcsb pdb:2XQW|rcsb pdb:2XWB|rcsb pdb:2XWJ|rcsb pdb:3D5R|rcsb pdb:3D5S|rcsb pdb:3G6J|rcsb pdb:3L3O|rcsb pdb:3L5N|rcsb pdb:3NMS|rcsb pdb:3OED|rcsb pdb:3OHX|rcsb pdb:3OXU|rcsb pdb:3RJ3|rcsb pdb:3T4A|rcsb pdb:4HW5|rcsb pdb:4HWJ|rcsb pdb:4I6O|rcsb pdb:4M76|rcsb pdb:4ONT|rcsb pdb:4ZH1|rcsb pdb:5FO7|rcsb pdb:5FO8|rcsb pdb:5FO9|rcsb pdb:5FOA|rcsb pdb:5FOB|rcsb pdb:5NBQ|rcsb pdb:5O32|rcsb pdb:5O35|rcsb pdb:6EHG|rcsb pdb:6RMT|rcsb pdb:6RMU|rcsb pdb:6RUR|rcsb pdb:6RUV|rcsb pdb:6S0B|rcsb pdb:6YO6|reactome:R-HSA-173736|reactome:R-HSA-174577|reactome:R-HSA-198933|reactome:R-HSA-375276|reactome:R-HSA-381426|reactome:R-HSA-418594|reactome:R-HSA-6798695|reactome:R-HSA-8957275|reactome:R-HSA-9660826|reactome:R-HSA-977606	-	chain-seq-start:19|chain-seq-end:330	-	figure legend:3C, 5C|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	rogid:6Axa89cCPpUXFsLnd7sCurZzLYI9606	rigid:zeXfsKUpC8/EQRYeg60HUj96epc	false	tag:n-n|his tag:n-n|v5 tag:c-c|mutation disrupting interaction strength:198-198,200-200|mutation disrupting interaction strength:220-220,223-223|mutation disrupting interaction strength:34-34,36-36,39-39	sufficient binding region:996-1306	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
uniprotkb:Q03591-PRO_0000005896	matrixdb:MULT_84_human	intact:EBI-22118464	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184654|imex:IM-27467-3	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:1302"(stable complex)	intact:EBI-3935840(chain-parent)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	-	chain-seq-start:19|chain-seq-end:330	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	figure legend:3D, 5D|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	-	-	false	tag:n-n|his tag:n-n|v5 tag:c-c|mutation disrupting interaction strength:198-198,200-200|mutation disrupting interaction strength:220-220,223-223|mutation disrupting interaction strength:34-34,36-36,39-39	-	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
matrixdb:MULT_84_human	uniprotkb:P08603-PRO_0000005894	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	intact:EBI-22114230	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:p08603-pro_0000005894(display_long)|uniprotkb:CFH(gene name)|psi-mi:CFH(display_short)|uniprotkb:HF(gene name synonym)|uniprotkb:HF1(gene name synonym)|uniprotkb:HF2(gene name synonym)|uniprotkb:H factor 1(gene name synonym)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0915"(physical association)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184672|imex:IM-27467-5	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:1302"(stable complex)	psi-mi:"MI:0326"(protein)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	intact:EBI-1223708(chain-parent)	-	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	chain-seq-start:19|chain-seq-end:1231	figure legend:3E,5E|comment:CFH-binding is inhibited in the presence of wild-type CFHR1 in a dose dependent manner. However, in the presence of the CFHR1 Mut1 and CFHR1 Mut2 proteins, no inhibition of CFH-binding to C3b can be observed.|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:XBVVm1S9GOtP5be24RqAkVBULzQ9606	-	false	-	his tag:n-n|tag:n-n|v5 tag:c-c	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
matrixdb:MULT_84_human	uniprotkb:Q03591-PRO_0000005896	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	intact:EBI-22118464	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0915"(physical association)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184672|imex:IM-27467-5	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0941"(competitor)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:1302"(stable complex)	psi-mi:"MI:0326"(protein)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	intact:EBI-3935840(chain-parent)	-	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	chain-seq-start:19|chain-seq-end:330	figure legend:3E,5E|comment:CFH-binding is inhibited in the presence of wild-type CFHR1 in a dose dependent manner. However, in the presence of the CFHR1 Mut1 and CFHR1 Mut2 proteins, no inhibition of CFH-binding to C3b can be observed.|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	-	false	-	tag:n-n|his tag:n-n|v5 tag:c-c|mutation disrupting interaction strength:198-198,200-200|mutation disrupting interaction strength:220-220,223-223|mutation decreasing interaction strength:34-34,36-36,39-39	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
uniprotkb:P08603-PRO_0000005894	matrixdb:MULT_84_human	intact:EBI-22114230	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	psi-mi:p08603-pro_0000005894(display_long)|uniprotkb:CFH(gene name)|psi-mi:CFH(display_short)|uniprotkb:HF(gene name synonym)|uniprotkb:HF1(gene name synonym)|uniprotkb:HF2(gene name synonym)|uniprotkb:H factor 1(gene name synonym)	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184702|imex:IM-27467-7	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:1302"(stable complex)	intact:EBI-1223708(chain-parent)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	-	chain-seq-start:19|chain-seq-end:1231	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	figure legend:3E|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	rogid:XBVVm1S9GOtP5be24RqAkVBULzQ9606	-	-	false	his tag:n-n|tag:n-n|v5 tag:c-c	-	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
uniprotkb:Q03591-PRO_0000005896	uniprotkb:P01024	intact:EBI-22118464	intact:EBI-905851|uniprotkb:A7E236|ensembl:ENSP00000245907	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:co3_human(display_long)|uniprotkb:C3(gene name)|psi-mi:C3(display_short)|uniprotkb:CPAMD1(gene name synonym)|uniprotkb:C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1(gene name synonym)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184726|imex:IM-27467-9	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:0326"(protein)	intact:EBI-3935840(chain-parent)	refseq:NP_000055.2|dip:DIP-35180N|ensembl:ENSG00000125730(gene)|ensembl:ENST00000245907(transcript)|go:"GO:0001798"(positive regulation of type IIa hypersensitivity)|go:"GO:0001934"(positive regulation of protein phosphorylation)|go:"GO:0001970"(positive regulation of activation of membrane attack complex)|go:"GO:0004866"(endopeptidase inhibitor activity)|go:"GO:0005102"(signaling receptor binding)|go:"GO:0005576"(extracellular region)|go:"GO:0005615"(extracellular space)|go:"GO:0005788"(endoplasmic reticulum lumen)|go:"GO:0005886"(plasma membrane)|go:"GO:0006631"(fatty acid metabolic process)|go:"GO:0006954"(inflammatory response)|go:"GO:0006955"(immune response)|go:"GO:0006956"(complement activation)|go:"GO:0006957"(complement activation, alternative pathway)|go:"GO:0006958"(complement activation, classical pathway)|go:"GO:0007165"(signal transduction)|go:"GO:0007186"(G protein-coupled receptor signaling pathway)|go:"GO:0009617"(response to bacterium)|go:"GO:0009986"(cell surface)|go:"GO:0010575"(positive regulation of vascular endothelial growth factor production)|go:"GO:0010828"(positive regulation of glucose transmembrane transport)|go:"GO:0010866"(regulation of triglyceride biosynthetic process)|go:"GO:0010884"(positive regulation of lipid storage)|go:"GO:0016322"(neuron remodeling)|go:"GO:0031715"(C5L2 anaphylatoxin chemotactic receptor binding)|go:"GO:0032991"(protein-containing complex)|go:"GO:0034774"(secretory granule lumen)|go:"GO:0035578"(azurophil granule lumen)|go:"GO:0035846"(oviduct epithelium development)|go:"GO:0045745"(positive regulation of G protein-coupled receptor signaling pathway)|go:"GO:0045766"(positive regulation of angiogenesis)|go:"GO:0048260"(positive regulation of receptor-mediated endocytosis)|go:"GO:0060100"(positive regulation of phagocytosis, engulfment)|go:"GO:0070062"(extracellular exosome)|go:"GO:0072562"(blood microparticle)|go:"GO:0097242"(amyloid-beta clearance)|go:"GO:0097278"(complement-dependent cytotoxicity)|go:"GO:0150062"(complement-mediated synapse pruning)|go:"GO:0150064"(vertebrate eye-specific patterning)|go:"GO:1905114"(cell surface receptor signaling pathway involved in cell-cell signaling)|go:"GO:2000427"(positive regulation of apoptotic cell clearance)|interpro:IPR000020(Anaphylatoxin/fibulin)|interpro:IPR001134(Netrin, C-terminal)|interpro:IPR001599(Alpha-2-macroglobulin)|interpro:IPR001840(Complement C3a/C4a/C5a anaphylatoxin)|interpro:IPR002890(Alpha-2-macroglobulin, N-terminal)|interpro:IPR008930(Terpenoid cylases/protein prenyltransferase alpha-alpha toroid)|interpro:IPR008993(TIMP-like, OB-fold)|interpro:IPR009048(Alpha-macroglobulin, receptor-binding)|interpro:IPR011625(Alpha-2-macroglobulin, N-terminal 2)|interpro:IPR011626(A-macroglobulin complement component)|interpro:IPR013783(Immunoglobulin-like fold)|interpro:IPR018081|interpro:IPR018933|interpro:IPR019742|interpro:IPR035711|interpro:IPR035815|interpro:IPR036595|interpro:IPR040839|interpro:IPR041425|interpro:IPR041555|mint:P01024|rcsb pdb:1C3D|rcsb pdb:1GHQ|rcsb pdb:1W2S|rcsb pdb:2A73|rcsb pdb:2A74|rcsb pdb:2GOX|rcsb pdb:2I07|rcsb pdb:2ICE|rcsb pdb:2ICF|rcsb pdb:2NOJ|rcsb pdb:2QKI|rcsb pdb:2WII|rcsb pdb:2WIN|rcsb pdb:2WY7|rcsb pdb:2WY8|rcsb pdb:2XQW|rcsb pdb:2XWB|rcsb pdb:2XWJ|rcsb pdb:3D5R|rcsb pdb:3D5S|rcsb pdb:3G6J|rcsb pdb:3L3O|rcsb pdb:3L5N|rcsb pdb:3NMS|rcsb pdb:3OED|rcsb pdb:3OHX|rcsb pdb:3OXU|rcsb pdb:3RJ3|rcsb pdb:3T4A|rcsb pdb:4HW5|rcsb pdb:4HWJ|rcsb pdb:4I6O|rcsb pdb:4M76|rcsb pdb:4ONT|rcsb pdb:4ZH1|rcsb pdb:5FO7|rcsb pdb:5FO8|rcsb pdb:5FO9|rcsb pdb:5FOA|rcsb pdb:5FOB|rcsb pdb:5NBQ|rcsb pdb:5O32|rcsb pdb:5O35|rcsb pdb:6EHG|rcsb pdb:6RMT|rcsb pdb:6RMU|rcsb pdb:6RUR|rcsb pdb:6RUV|rcsb pdb:6S0B|rcsb pdb:6YO6|reactome:R-HSA-173736|reactome:R-HSA-174577|reactome:R-HSA-198933|reactome:R-HSA-375276|reactome:R-HSA-381426|reactome:R-HSA-418594|reactome:R-HSA-6798695|reactome:R-HSA-8957275|reactome:R-HSA-9660826|reactome:R-HSA-977606	-	chain-seq-start:19|chain-seq-end:330	-	figure legend:4B|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	rogid:6Axa89cCPpUXFsLnd7sCurZzLYI9606	rigid:zeXfsKUpC8/EQRYeg60HUj96epc	false	tag:n-n|his tag:n-n|v5 tag:c-c	mutation disrupting interaction strength:1105-1105|mutation decreasing interaction strength:1110-1110|mutation disrupting interaction strength:1110-1110,1115-1115|mutation disrupting interaction strength:1114-1114|mutation decreasing interaction strength:1115-1115|sufficient binding region:996-1306|mutation increasing interaction strength:1163-1163|mutation decreasing interaction strength:1171-1171|mutation disrupting interaction strength:1029-1029|mutation increasing interaction strength:1153-1153|mutation with no effect:1156-1156|mutation with no effect:1156-1157|mutation increasing interaction strength:1285-1285	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
matrixdb:MULT_84_human	uniprotkb:P08603-2	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	intact:EBI-12684810	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:p08603-2(display_long)|uniprotkb:CFH(gene name)|psi-mi:CFH(display_short)|uniprotkb:HF(gene name synonym)|uniprotkb:HF1(gene name synonym)|uniprotkb:HF2(gene name synonym)|uniprotkb:FHL-1(isoform synonym)|uniprotkb:H factor 1(gene name synonym)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0915"(physical association)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184990|imex:IM-27467-13	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:1302"(stable complex)	psi-mi:"MI:0326"(protein)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	intact:EBI-1223708(isoform-parent)|uniprotkb:P08603-2(isoform-parent)	-	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	-	figure legend:6A|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:5z5TurtXwYSuzypYW+AWJDzcgso9606	-	false	-	tag:n-n|his tag:n-n|v5 tag:c-c|sufficient binding region:19-449	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
matrixdb:MULT_84_human	uniprotkb:Q03591-PRO_0000005896	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	intact:EBI-22118464	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0915"(physical association)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184990|imex:IM-27467-13	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0941"(competitor)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:1302"(stable complex)	psi-mi:"MI:0326"(protein)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	intact:EBI-3935840(chain-parent)	-	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	chain-seq-start:19|chain-seq-end:330	figure legend:6A|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	-	false	-	tag:n-n|his tag:n-n|v5 tag:c-c	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
uniprotkb:P08603-2	matrixdb:MULT_84_human	intact:EBI-12684810	intact:EBI-12735745|wwpdb:5fo7|wwpdb:3g6j|wwpdb:2i07|reactome:R-HSA-166832	psi-mi:p08603-2(display_long)|uniprotkb:CFH(gene name)|psi-mi:CFH(display_short)|uniprotkb:HF(gene name synonym)|uniprotkb:HF1(gene name synonym)|uniprotkb:HF2(gene name synonym)|uniprotkb:FHL-1(isoform synonym)|uniprotkb:H factor 1(gene name synonym)	psi-mi:c3b_human(display_short)|psi-mi:MULT_84_human(display_long)|intact:Complement C3b complex(complex recommended name)|intact:C3b dimer(complex systematic name)	psi-mi:"MI:0411"(enzyme linked immunosorbent assay)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22185029|imex:IM-27467-15	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:1302"(stable complex)	intact:EBI-1223708(isoform-parent)|uniprotkb:P08603-2(isoform-parent)	pubmed:27782329(see-also)|pubmed:6225800(see-also)|evidence ontology:"ECO:0000353"|efo:"Orphanet:280133"(see-also)|efo:"Orphanet:2134"(see-also)|efo:"Orphanet:93575"(see-also)|efo:"EFO:0001365"(see-also)|pubmed:27013439(see-also)|pubmed:19196712(see-also)|pubmed:17051160(see-also)|go:"GO:0005615"(extracellular space)|go:"GO:0001848"(complement binding)|go:"GO:1903028"(positive regulation of opsonization)|go:"GO:0006956"(complement activation)|go:"GO:0050766"(positive regulation of phagocytosis)|go:"GO:0044533"(positive regulation of apoptotic process in another organism)|go:"GO:0050778"(positive regulation of immune response)|go:"GO:0030449"(regulation of complement activation)|go:"GO:0008228"(opsonization)|pubmed:6559201(see-also)|pubmed:15454921(see-also)|pubmed:21205667(see-also)|pubmed:17051150(see-also)|complex portal:CPX-973(complex-primary)|pubmed:26489954(see-also)	-	-	curated-complex:"A protein complex of the alternative pathway of complement activation of the innate immune system. Complement C3 precurser is activated by cleavage into C3a and C3b by C3 convertases, either C4bC2a in the classical and lectin pathways or C3(H2O)Bb, C3bBb, C3bBbC3b, C3bBbP or C3bBbC3bP in the alternative pathway.     C3b acts as an opsonin and interacts with glycoproteins and carbohydrates on pathogenic or apoptotic target cell surfaces through its reactive thioester moiety. Opsonization of target cells leads to enhanced phagocytosis, lysis of target cells via membrane attack complex (CPX-6159) assembly, clearance of antibody-antigen complexes and up-regulation of the adaptive response.     Activation of C3b leads to an amplification cascade that generates more C3 convertase, deposits more C3b at the local site and switches C3 convertases to C5 convertases.     To protect host cells from inadvertent complement activation the activation of C3b is tightly regulated by either disrupting the C3 convertases or aiding in the proteolytic degradation of C3b. Bacteria and viruses possess C3b proteases to evade the complement response.     Lack of protection, due to familial mutations in the complement genes or the presence of autoantibodies against regulators has been linked to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and age-related macular degeneration (AMD) in eyes. Conditions of chronic and acute inflammations, as in rheumatoid arthritis, strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue."|complex-properties:"The alternative pathway is continuously activated at a low level. C3 precursor is first processed by the removal of 4 Arg residues and spontaneous hydrolysis due to the breakdown of the internal thioester bond forms C3(H2O) (disulfide bonded P01024-PRO_0000005909 & P01024-PRO_0000005908).     C3(H2O) subsequently binds factor B that is cleaved by Factor D (P00746) into 2 fragments: CFBa and CFBb. CFBb, a serine protease, then combines with complement factor C3(H2O) or C3b to generate the C3 or C5 convertases.     Proteolytic cleavage of C3 to C3b is accompanied by large conformational changes that result in the exposure of cryptic binding sites required for convertase assembly and regulation. This includes a significant movement of the thioester-bond-containing domain through which C3b attaches to target surfaces."|complex-assembly:Heterodimer|disease:"Complement component 3 (C3) deficiency [Orphanet:280133]: a rare, autosomal recessive defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis."|disease:"Atypical hemolytic-uremic syndrome with C3 anomaly [Orphanet:2134 & Orphanet:93575]: an autosomal dominant, atypical form of hemolytic-uremic syndrome (aHUS, a thrombotic microangiopathy) characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction."|disease:"Age-related macular degeneration [EFO:0001365]: age-related macular degeneration usually in older adults which results in a loss of vision in the center of the visual field (the macula lutea) because of damage to the retina. Manifests as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Occurs in dry and wet forms. Most common cause of irreversible vision loss in the developed world."	figure legend:6A|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	rogid:5z5TurtXwYSuzypYW+AWJDzcgso9606	-	-	false	tag:n-n|his tag:n-n|v5 tag:c-c|sufficient binding region:19-449	-	-	-	psi-mi:"MI:0421"(identification by antibody)	psi-mi:"MI:0421"(identification by antibody)
uniprotkb:Q03591-PRO_0000005896	uniprotkb:Q03591-PRO_0000005896	intact:EBI-22118464	intact:EBI-22118464	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:"MI:0071"(molecular sieving)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:9606(human)|taxid:9606(Homo sapiens)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22184778|imex:IM-27467-11	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:0326"(protein)	intact:EBI-3935840(chain-parent)	intact:EBI-3935840(chain-parent)	-	chain-seq-start:19|chain-seq-end:330	chain-seq-start:19|chain-seq-end:330	figure legend:5B|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:9606(human-293f)|taxid:9606(Homo sapiens HEK293F cell line)	-	2019/10/06	2019/11/19	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	rigid:6MKrAgXm1A/Qsl0tjI0C+dnCVgA	false	mutation disrupting interaction strength:34-34,36-36,39-39|tag:n-n|his tag:n-n|v5 tag:c-c|glycosylated residue:?-?	mutation disrupting interaction strength:34-34,36-36,39-39|tag:n-n|his tag:n-n|v5 tag:c-c|glycosylated residue:?-?	2	0	psi-mi:"MI:0396"(predetermined participant)	psi-mi:"MI:0396"(predetermined participant)
chebi:"CHEBI:28304"	uniprotkb:Q03591-PRO_0000005896	intact:EBI-1379423	intact:EBI-22118464	psi-mi:heparin(display_short)|psi-mi:"CHEBI:28304"(display_long)	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:"MI:0096"(pull down)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:-2(chemical synthesis)|taxid:-2("Chemical synthesis (Chemical synthesis)")	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0407"(direct interaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22185057|imex:IM-27467-17	-	-	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0328"(small molecule)	psi-mi:"MI:0326"(protein)	-	intact:EBI-3935840(chain-parent)	-	-	chain-seq-start:19|chain-seq-end:330	figure legend:6B|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	-	false	-	tag:n-n|his tag:n-n|v5 tag:c-c	-	-	psi-mi:"MI:0818"(molecular weight estimation by coomasie staining)	psi-mi:"MI:0818"(molecular weight estimation by coomasie staining)
chebi:"CHEBI:28304"	uniprotkb:P01024	intact:EBI-1379423	intact:EBI-905851|uniprotkb:A7E236|ensembl:ENSP00000245907	psi-mi:heparin(display_short)|psi-mi:"CHEBI:28304"(display_long)	psi-mi:co3_human(display_long)|uniprotkb:C3(gene name)|psi-mi:C3(display_short)|uniprotkb:CPAMD1(gene name synonym)|uniprotkb:C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1(gene name synonym)	psi-mi:"MI:0096"(pull down)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:-2(chemical synthesis)|taxid:-2("Chemical synthesis (Chemical synthesis)")	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0915"(physical association)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22185077|imex:IM-27467-19	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0328"(small molecule)	psi-mi:"MI:0326"(protein)	-	refseq:NP_000055.2|dip:DIP-35180N|ensembl:ENSG00000125730(gene)|ensembl:ENST00000245907(transcript)|go:"GO:0001798"(positive regulation of type IIa hypersensitivity)|go:"GO:0001934"(positive regulation of protein phosphorylation)|go:"GO:0001970"(positive regulation of activation of membrane attack complex)|go:"GO:0004866"(endopeptidase inhibitor activity)|go:"GO:0005102"(signaling receptor binding)|go:"GO:0005576"(extracellular region)|go:"GO:0005615"(extracellular space)|go:"GO:0005788"(endoplasmic reticulum lumen)|go:"GO:0005886"(plasma membrane)|go:"GO:0006631"(fatty acid metabolic process)|go:"GO:0006954"(inflammatory response)|go:"GO:0006955"(immune response)|go:"GO:0006956"(complement activation)|go:"GO:0006957"(complement activation, alternative pathway)|go:"GO:0006958"(complement activation, classical pathway)|go:"GO:0007165"(signal transduction)|go:"GO:0007186"(G protein-coupled receptor signaling pathway)|go:"GO:0009617"(response to bacterium)|go:"GO:0009986"(cell surface)|go:"GO:0010575"(positive regulation of vascular endothelial growth factor production)|go:"GO:0010828"(positive regulation of glucose transmembrane transport)|go:"GO:0010866"(regulation of triglyceride biosynthetic process)|go:"GO:0010884"(positive regulation of lipid storage)|go:"GO:0016322"(neuron remodeling)|go:"GO:0031715"(C5L2 anaphylatoxin chemotactic receptor binding)|go:"GO:0032991"(protein-containing complex)|go:"GO:0034774"(secretory granule lumen)|go:"GO:0035578"(azurophil granule lumen)|go:"GO:0035846"(oviduct epithelium development)|go:"GO:0045745"(positive regulation of G protein-coupled receptor signaling pathway)|go:"GO:0045766"(positive regulation of angiogenesis)|go:"GO:0048260"(positive regulation of receptor-mediated endocytosis)|go:"GO:0060100"(positive regulation of phagocytosis, engulfment)|go:"GO:0070062"(extracellular exosome)|go:"GO:0072562"(blood microparticle)|go:"GO:0097242"(amyloid-beta clearance)|go:"GO:0097278"(complement-dependent cytotoxicity)|go:"GO:0150062"(complement-mediated synapse pruning)|go:"GO:0150064"(vertebrate eye-specific patterning)|go:"GO:1905114"(cell surface receptor signaling pathway involved in cell-cell signaling)|go:"GO:2000427"(positive regulation of apoptotic cell clearance)|interpro:IPR000020(Anaphylatoxin/fibulin)|interpro:IPR001134(Netrin, C-terminal)|interpro:IPR001599(Alpha-2-macroglobulin)|interpro:IPR001840(Complement C3a/C4a/C5a anaphylatoxin)|interpro:IPR002890(Alpha-2-macroglobulin, N-terminal)|interpro:IPR008930(Terpenoid cylases/protein prenyltransferase alpha-alpha toroid)|interpro:IPR008993(TIMP-like, OB-fold)|interpro:IPR009048(Alpha-macroglobulin, receptor-binding)|interpro:IPR011625(Alpha-2-macroglobulin, N-terminal 2)|interpro:IPR011626(A-macroglobulin complement component)|interpro:IPR013783(Immunoglobulin-like fold)|interpro:IPR018081|interpro:IPR018933|interpro:IPR019742|interpro:IPR035711|interpro:IPR035815|interpro:IPR036595|interpro:IPR040839|interpro:IPR041425|interpro:IPR041555|mint:P01024|rcsb pdb:1C3D|rcsb pdb:1GHQ|rcsb pdb:1W2S|rcsb pdb:2A73|rcsb pdb:2A74|rcsb pdb:2GOX|rcsb pdb:2I07|rcsb pdb:2ICE|rcsb pdb:2ICF|rcsb pdb:2NOJ|rcsb pdb:2QKI|rcsb pdb:2WII|rcsb pdb:2WIN|rcsb pdb:2WY7|rcsb pdb:2WY8|rcsb pdb:2XQW|rcsb pdb:2XWB|rcsb pdb:2XWJ|rcsb pdb:3D5R|rcsb pdb:3D5S|rcsb pdb:3G6J|rcsb pdb:3L3O|rcsb pdb:3L5N|rcsb pdb:3NMS|rcsb pdb:3OED|rcsb pdb:3OHX|rcsb pdb:3OXU|rcsb pdb:3RJ3|rcsb pdb:3T4A|rcsb pdb:4HW5|rcsb pdb:4HWJ|rcsb pdb:4I6O|rcsb pdb:4M76|rcsb pdb:4ONT|rcsb pdb:4ZH1|rcsb pdb:5FO7|rcsb pdb:5FO8|rcsb pdb:5FO9|rcsb pdb:5FOA|rcsb pdb:5FOB|rcsb pdb:5NBQ|rcsb pdb:5O32|rcsb pdb:5O35|rcsb pdb:6EHG|rcsb pdb:6RMT|rcsb pdb:6RMU|rcsb pdb:6RUR|rcsb pdb:6RUV|rcsb pdb:6S0B|rcsb pdb:6YO6|reactome:R-HSA-173736|reactome:R-HSA-174577|reactome:R-HSA-198933|reactome:R-HSA-375276|reactome:R-HSA-381426|reactome:R-HSA-418594|reactome:R-HSA-6798695|reactome:R-HSA-8957275|reactome:R-HSA-9660826|reactome:R-HSA-977606	-	-	-	figure legend:6B|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:6Axa89cCPpUXFsLnd7sCurZzLYI9606	-	false	-	sufficient binding region:996-1306	-	-	psi-mi:"MI:0818"(molecular weight estimation by coomasie staining)	psi-mi:"MI:0818"(molecular weight estimation by coomasie staining)
chebi:"CHEBI:28304"	uniprotkb:Q03591-PRO_0000005896	intact:EBI-1379423	intact:EBI-22118464	psi-mi:heparin(display_short)|psi-mi:"CHEBI:28304"(display_long)	psi-mi:q03591-pro_0000005896(display_long)|uniprotkb:CFHR1(gene name)|psi-mi:CFHR1(display_short)|uniprotkb:CFHL(gene name synonym)|uniprotkb:CFHL1(gene name synonym)|uniprotkb:CFHL1P(gene name synonym)|uniprotkb:CFHR1P(gene name synonym)|uniprotkb:FHR1(gene name synonym)|uniprotkb:HFL1(gene name synonym)|uniprotkb:HFL2(gene name synonym)|uniprotkb:H factor-like protein 1(gene name synonym)|uniprotkb:H36(gene name synonym)	psi-mi:"MI:0096"(pull down)	Hannan et al. (2015)	imex:IM-27467|pubmed:27814381	taxid:-2(chemical synthesis)|taxid:-2("Chemical synthesis (Chemical synthesis)")	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0915"(physical association)	psi-mi:"MI:0469"(IntAct)	intact:EBI-22185077|imex:IM-27467-19	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0496"(bait)	psi-mi:"MI:0498"(prey)	psi-mi:"MI:0328"(small molecule)	psi-mi:"MI:0326"(protein)	-	intact:EBI-3935840(chain-parent)	-	-	chain-seq-start:19|chain-seq-end:330	figure legend:6B|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2019/10/06	2019/11/06	-	rogid:7RtKoQCvikrQBECNOm9UO6UGCv09606	-	false	-	tag:n-n|his tag:n-n|v5 tag:c-c	-	-	psi-mi:"MI:0818"(molecular weight estimation by coomasie staining)	psi-mi:"MI:0818"(molecular weight estimation by coomasie staining)